{"entity":{"id":"nct05624918","kind":"trial","name":"A Study of NovoTTF-200T(P) in Combination With Gemcitabine and Nab-Paclitaxel for Resectable Pancreatic Adenocarcinoma","aka":[],"tldr":"A phase 2 trial of nab-paclitaxel, gemcitabine and optune / Optune Pax (TTFields) in pancreatic cancer, run by Ashish Manne, now recruiting.","summary":"A Study of NovoTTF-200T(P) in Combination With Gemcitabine and Nab-Paclitaxel for Resectable Pancreatic Adenocarcinoma is a phase 2, interventional study registered as NCT05624918 by Ashish Manne, with a registry enrolment figure of 38 participants, started 2024-07-01 and due to reach its primary completion in 2027-08-29. Interventions recorded: Nab paclitaxel; Gemcitabine; NovoTTF-200T(P). Conditions listed: Pancreatic Adenocarcinoma; Resectable Pancreatic Cancer. Primary outcome: 2 Year Overall Survival (OS); Rate of Resection. Pancreatic eligibility wording from the registry: \"* Histological or cytological evidence of pancreatic adenocarcinoma\". Sites: United States. No results are recorded here; the registry entry is the source.","status":"recruiting","asOf":"2026-09-24","links":[{"label":"ClinicalTrials.gov NCT05624918","url":"https://clinicaltrials.gov/study/NCT05624918"}],"tags":["ctgov-ingest","pancreatic-deep-dive"],"related":[],"cancers":["resectable-pdac"],"sections":[],"technologies":["cytotoxic-chemotherapy","ttfields"],"targets":[],"drugs":["nab-paclitaxel","gemcitabine","optune"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT05624918","phase":"2","setting":"A Phase II Study of Peri-Operative NovoTTF-200T(P) in Combination With Gemcitabine and Nab-Paclitaxel for Resectable Pancreatic Adenocarcinoma","sponsor":"Ashish Manne","enrolled":38,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct05624918/","neighbours":{"cancer":[{"id":"resectable-pdac","kind":"cancer","name":"Resectable pancreatic ductal adenocarcinoma","route":"/cancers/resectable-pdac/"}],"technology":[{"id":"cytotoxic-chemotherapy","kind":"technology","name":"Cytotoxic chemotherapy","route":"/technologies/cytotoxic-chemotherapy/"},{"id":"ttfields","kind":"technology","name":"Tumour treating fields (TTFields)","route":"/technologies/ttfields/"}],"drug":[{"id":"gemcitabine","kind":"drug","name":"Gemcitabine","route":"/drugs/gemcitabine/"},{"id":"nab-paclitaxel","kind":"drug","name":"Nab-paclitaxel","route":"/drugs/nab-paclitaxel/"},{"id":"optune","kind":"drug","name":"Optune / Optune Pax (TTFields)","route":"/drugs/optune/"}],"term":[{"id":"pancreatic-trials-open-today","kind":"term","name":"Pancreatic cancer trials open today (registry snapshot and UK sites)","route":"/terms/pancreatic-trials-open-today/"}]}}